Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complication.

ABSTRACT: Virus-specific T cells (VST) from partially-HLA matched donors have been effective for treatment of refractory viral infections in immunocompromised patients in prior studies with a good safety profile, but rare adverse events have been described. Here we describe a unique and severe adverse event of VST therapy in an infant with severe combined immunodeficiency, who receives, as part of a clinical trial (NCT03475212), third party VSTs for treating cytomegalovirus viremia following bone marrow transplantation. At one-month post-VST infusion, rejection of graft and reversal of chimerism is observed, as is an expansion of T cells exclusively from the VST donor. Single-cell gene expression and T cell receptor profiling demonstrate a narrow repertoire of predominantly activated CD4⁺

SUBMITTER: Keller MD 

PROVIDER: S-EPMC10980733 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature